Comparing Conexeu Sciences (NASDAQ:CNXU) and Axe Compute (NASDAQ:AGPU)

Axe Compute (NASDAQ:AGPU) and Conexeu Sciences (NASDAQ:CNXU) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, earnings, risk and analyst recommendations.

Valuation & Earnings

This table compares Axe Compute and Conexeu Sciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axe Compute	$120,000.00	698.59	-$233.10 million	($8.18)	-0.90
Conexeu Sciences	N/A	N/A	N/A	($0.11)	-92.73

Conexeu Sciences has lower revenue, but higher earnings than Axe Compute. Conexeu Sciences is trading at a lower price-to-earnings ratio than Axe Compute, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

9.0% of Axe Compute shares are owned by institutional investors. 1.2% of Axe Compute shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Axe Compute and Conexeu Sciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axe Compute	1	0	0	0	1.00
Conexeu Sciences	0	1	1	0	2.50

Conexeu Sciences has a consensus price target of $20.00, suggesting a potential upside of 96.08%. Given Conexeu Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Conexeu Sciences is more favorable than Axe Compute.

Profitability

This table compares Axe Compute and Conexeu Sciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Axe Compute	-470,383.31%	-7,363.67%	-626.32%
Conexeu Sciences	N/A	N/A	N/A

Summary

Conexeu Sciences beats Axe Compute on 7 of the 11 factors compared between the two stocks.

About Axe Compute

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient’s body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

About Conexeu Sciences

Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. — Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property (“IP”) developed over more than a decade at the University of British Columbia (the “University”) and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University’s right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company’s only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix (“ECM”) formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the “10 Minute Tissue™” concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration (“FDA”) clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada.